Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Bicara Therapeutics Inc shares valued at $226,942 were sold by Cohlhepp Ryan on Oct 15 ’25. At $18.16 per share, Cohlhepp Ryan sold 12,500 shares. The insider’s holdings dropped to 198,141 shares worth approximately $2.89 million following the completion of this transaction.
Also, Mazumdar Claire purchased 24,103 shares, netting a total of over 453,761 in proceeds.
Before that, Mazumdar Claire had sold 13,289 shares from its account. In a trade valued at $250,391, the Chief Executive Officer traded Bicara Therapeutics Inc shares for $18.84 each. Upon closing the transaction, the insider’s holdings decreased to 13,289 shares, worth approximately $4.52 million.
As published in their initiating research note from Piper Sandler on August 19, 2025, Bicara Therapeutics Inc [BCAX] has been an Overweight and the price target has been revised to $36. Analysts at Wells Fargo upgraded the stock from ‘”an Underweight”‘ to ‘”an Equal weight”‘ outlook in a report released in late May. As of April 17, 2025, Wells Fargo has initiated its “an Underweight” rating for BCAX. Earlier on February 06, 2025, Wedbush initiated its rating. Their recommendation was “an Outperform” for BCAX stock.
Analyzing BCAX Stock Performance
On last trading session, Bicara Therapeutics Inc [NASDAQ: BCAX] rose 3.04% to $14.57. The stock’s lowest price that day was $13.95, but it reached a high of $14.965 in the same session. During the last five days, there has been a drop of approximately -11.48%. Over the course of the year, Bicara Therapeutics Inc shares have dropped approximately -41.65%. Shares of the company reached a 52-week high of $19.71 on 10/13/25 and a 52-week low of $7.80 on 05/23/25.
Support And Resistance Levels for Bicara Therapeutics Inc (BCAX)
According to the 24-hour chart, there is a support level at 14.02, which, if violated, would cause prices to drop to 13.48. In the upper region, resistance lies at 15.04. The next price resistance is at 15.51. RSI (Relative Strength Index) is 42.03 on the 14-day chart, showing neutral technical sentiment.
Is Bicara Therapeutics Inc subject to short interest?
Stocks of Bicara Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 9868.0 shares to 5.68 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 5.67 million shares. A jump of 0.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.56 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.56.
Which companies own the most shares of Bicara Therapeutics Inc (BCAX)?
In terms of Bicara Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 24 in the next 12 months, up nearly 69.73% from the previous closing price of $14.14. Analysts anticipate Bicara Therapeutics Inc stock to reach 40 by 2025, with the lowest price target being 8. On December 06, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $42.
